- Home
- TRSG vs CMMB Comparison
TRSG vs CMMB Comparison
Compare TRSG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRSG
- CMMB
- Stock Information
- Founded
- TRSG 1996
- CMMB 2004
- Country
- TRSG Singapore
- CMMB Israel
- Employees
- TRSG N/A
- CMMB 16
- Industry
- TRSG
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- TRSG
- CMMB Health Care
- Exchange
- TRSG NYSE
- CMMB Nasdaq
- Market Cap
- TRSG 25.8M
- CMMB 23.0M
- IPO Year
- TRSG 2024
- CMMB N/A
- Fundamental
- Price
- TRSG $1.85
- CMMB $1.17
- Analyst Decision
- TRSG
- CMMB Strong Buy
- Analyst Count
- TRSG 0
- CMMB 2
- Target Price
- TRSG N/A
- CMMB $9.00
- AVG Volume (30 Days)
- TRSG 29.3K
- CMMB 88.8K
- Earning Date
- TRSG 12-31-2024
- CMMB 05-20-2025
- Dividend Yield
- TRSG N/A
- CMMB N/A
- EPS Growth
- TRSG N/A
- CMMB N/A
- EPS
- TRSG N/A
- CMMB N/A
- Revenue
- TRSG $14,441,864.00
- CMMB N/A
- Revenue This Year
- TRSG N/A
- CMMB N/A
- Revenue Next Year
- TRSG N/A
- CMMB N/A
- P/E Ratio
- TRSG N/A
- CMMB N/A
- Revenue Growth
- TRSG 9.34
- CMMB N/A
- 52 Week Low
- TRSG $1.00
- CMMB $0.60
- 52 Week High
- TRSG $6.96
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- TRSG N/A
- CMMB 50.52
- Support Level
- TRSG N/A
- CMMB $1.15
- Resistance Level
- TRSG N/A
- CMMB $1.31
- Average True Range (ATR)
- TRSG 0.00
- CMMB 0.08
- MACD
- TRSG 0.00
- CMMB -0.00
- Stochastic Oscillator
- TRSG 0.00
- CMMB 37.09
About TRSG TUNGRAY TECHNOLOGIES INC
Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.